It was interesting to see that this blog The Niche was cited in the lawsuit filing by the DOJ in the U.S.A. vs. California Stem Cell Treatment Center, Cell Surgical Network (CSN), et al. case. Yeah, that lawsuit. This suit is part of the DOJ action yesterday that along with the other suit against US Stem Cell […]
DOJ cites The Niche blog in suit vs. stem cell clinic firm: what’s scoop? Read More »
I emailed the CSO of US Stem Cell, Kristin Comella, for any reaction to today’s big news of the DOJ filing suit against two stem cell clinic firms including hers seeking injunctions. I also emailed the leaders of the other firm, California Stem Cell Treatment Center/Cell Surgical Network. It’s important to include the clinic firms’
Responses From Both US Stem Cell & Cell Surgical Network to DOJ Action Read More »
The DOJ and FDA are seeking permanent injunctions in federal court against two of the most widespread and influential of the for-profit, unproven stem cell clinic firms in the U.S. This story is breaking so I’ll have more later this week. The take home is that I see this action as a positive, probably historic turning point
In historic step, FDA & DOJ seek injunctions on 2 key unproven stem cell clinic firms Read More »
Three recent media pieces on unproven, for-profit stem cell clinics paint an unflattering picture of this industry. At the intersection of these pieces is the clinic “treatment” consisting of fat stem cells (being manufactured as in a screenshot at right from a clinic YouTube video), a product the FDA has indicated is most often going
New stem cell clinic insights from trio of critical media pieces Read More »
The last few years for the publicly-traded stem cell clinic biz, US Stem Cell, Inc., which goes by the ticker $USRM, have seemed like a rollercoaster to me as an observer. I can see four main areas of news that to me make the future seem uncertain for this firm. First, the US Stem was linked to the
Clinic biz US Stem Cell reports SEC subpoena, adding to uncertainty on its future Read More »
Early in 2016, we started hearing about patient allegations of having been blinded in Florida by at least one stem cell business and several allegations seemed linked to a publicly-traded company called U.S. Stem Cell, Inc. (USRM). In turn, there have been a number of lawsuits involving USRM, including one filed just a few months
Sen. Grassley asks tough questions for FDA on U.S. Stem Cell, blinded women Read More »
Every year I look into my stem cell crystal ball and make predictions for our field including regenerative medicine. Well, I don’t really look into a crystal ball, but I try to use a combination of what I’m hearing through the grapevine, stuff I’m reading, some info that is not yet in the public domain,
20 predictions for stem cells & regenerative medicine in 2018 Read More »
Each year I make a list of predictions for the year to come for the stem cell and regenerative medicine field. Then about a year later I grade myself on how I did as that year winds down. Here’s how I did in 2016. For 2017, late in 2016 I made 20 stem cell predictions. Let’s
Grading my twenty 2017 stem cell predictions Read More »
When you think of Florida, what else crosses your mind first? Orange juice? Heat and humidity? Beaches? Disney? I don’t know if this says more about me or the state, but these days I think of stem cells. Florida and California are the two biggest hotbeds of the for-profit stem cell clinic world, each with
Sentinel Takes Investigational Deep Dive into Florida Stem Cell Clinic Soup Read More »
Can a stem cell clinic business get FDA RMAT designation? At least one announced it was trying, but now seems to have given up. Stem cell clinic business US Stem Cell, Inc. has reportedly announced that it is at least temporarily abandoning its efforts at getting Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The
US Stem Cell bid for FDA RMAT rejected? Read More »